Loading MRK detail
Loading ticker data...
Loading MRK detail
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV.
Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Chart data unavailable
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals, Inc. (NasdaqGS: TERN) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Terns will receive $53.00 in cash for each share of Terns that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.
GAAP earnings, despite popular opinion, don't accurately measure profits. Companies can, and do, manipulate GAAP earnings through accounting rule loopholes.
BOCHK Asset Management Ltd purchased a new position in Merck and Co., Inc. (NYSE: MRK) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,000 shares of the company's stock, valued at approximately $1,895,000. Merck and Co., Inc.
Cardinal Capital Management Inc. raised its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 3.6% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 304,534 shares of the company's stock after purchasing an additional 10,659 shares during the
Though both dominate oncology, a stronger growth outlook and clearer targets may give AstraZeneca an edge over Merck.
Franklin Street Advisors Inc. NC lifted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 462.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,541 shares of the company's stock after buying an additional
The latest trading day saw Merck (MRK) settling at $119.28, representing a -1.3% change from its previous close.
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Two stocks retirement investors typically reach for in uncertain markets have risen notably in recent months.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). On March 25, 2026, Merck announced that it had entered into a definitive agreement to acquire Terns. Upon the successful closing of the tender offer, stockholders of Terns will receive $53.00 net in cash for each share of Te.
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Leo Wealth LLC increased its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 29.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,848 shares of the company's stock after buying an additional 6,078 shares during the quarter. Leo Wealth
Savvy Advisors Inc. grew its position in shares of Merck and Co., Inc. (NYSE: MRK) by 50.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,567 shares of the company's stock after buying an additional 8,627 shares during
The drugmaker's stock recently got a shot in the arm on the news of it acquiring Terns Pharmaceutical—a move that will not only bolster its cancer treatment pipeline but also reinforce Merck's role as a top-tier serial acquirer.
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.26%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.
